Rapport Therapeutics Inc (RAPP)

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

BOSTON and SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport”...

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update

Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting

Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median...

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities